PRISM BioLab (206A) · PolicyRestated
Prioritizing research and development funding and maintaining a no-dividend policy for the time being
First written in FY2024. 3 of 4 entries say "Restated". Latest entry: 2026-05-14.
4entries
3years
1from disclosures
How it moved
Same theme, other companies
No-Dividend Policy Prioritizing R&D FundingA theme 36 companies write about · 8 as a headwind · 19 as a tailwind
The whole theme swung hardest in 2025: 2 of 19 companies on the "Worse" side.
31 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 36 companies compared. The sentences above are computed from all 36.Full recordFilings, disclosures and news, newest first
- 2026-05-14RestatedEarnings
「FY2026 (forecast) — 0.00」
The annual dividend forecast for the fiscal year ending September 2026 was ¥0, indicating that the company remains without a dividend. - FY2025RestatedAnnual report
「Because research and development activities in each research field must continue, our policy is to prioritize securing funds, and no dividends are planned at this stage.」
The policy of prioritizing research and development funding and paying no dividends for the time being was reaffirmed. - FY2025-H1RestatedAnnual report
「The dividend per share is not presented because no dividends have been paid.」
No dividends were paid during the interim accounting period. - FY2024First statedAnnual report
「Because research and development activities in each research field must continue, our policy is to prioritize securing funds, and no dividends are planned at this stage.」
The company says it will consider paying dividends if it can generate stable earnings in the future.